Merck & Co. Inc. has announced that the U.S. Centers for Disease Control and Prevention $(CDC)$ Advisory Committee on Immunization Practices (ACIP) has voted to recommend ENFLONSIA™ (clesrovimab-cfor) for preventing respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months who are born during or entering their first RSV season. The recommendation includes ENFLONSIA in the Vaccines for Children Program, ensuring broader access for infants. This follows the U.S. Food and Drug Administration's approval of ENFLONSIA based on clinical trials. Merck plans to start ordering in July 2025, with deliveries before the 2025-2026 RSV season. The ACIP's recommendation is provisional, pending final approval by the CDC Director or Health and Human Services Secretary.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。